Dermatology

Your Article Summary

See Latest Articles

Identification of modifier genes for cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations
International Journal of Cancer, 07/27/09

Yang XR et al. – These findings support the hypothesis that common genetic polymorphisms in DNA repair, apoptosis and immune response pathways may modify the risk of cutaneous malignant melanoma (CMM) in CMM-prone families with or without CDKN2A mutations.

• Aim was to identify modifier genes for CMM in CMM-prone families with or w/o CDKN2A mutations
• 537 individuals (107 CMM) from 28 families (19 CDKN2A+, 9 CDKN2A-)
• They were genotyped for 1,536 SNPs in 152 genes involved in DNA repair, apoptosis and immune response pathways
• Conditional logistic regression: to account for family ascertainment and differences in disease prevalence among families
• Pathway- and gene-based permutation analyses to assess the risk of CMM associated with genes in the 5 pathways: DNA repair, apoptosis, TNF/NFB, TH1:TH2 and other immune regulation

• Some candidate genes such as FAS, BCL7A, CASP14, TRAF6, WRN, IL9, IL10RB, TNFSF8, TNFRSF9 and JAK3 were associated with CMM risk
• After correction for multiple comparisons, IL9 remained significant
• Effects of some genes were stronger in CDKN2A-positive families (BCL7A and IL9); some were stronger in CDKN2A-negative families (BCL2L1)

Related Articles

See all related articles

Patterns of GRP78 and MTJ1 expression in primary cutaneous malignant melanoma
Modern Pathology, 10/23/09    Relevance Score: 81%

Metastatic cutaneous malignant melanoma: Spectrum of imaging findings and the role of multimodality imaging
Journal of Medical Imaging and Radiation Oncology (JMIRO), 10/05/09    Relevance Score: 81%

Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies
Expert Review of Anticancer Therapy, 11/12/09    Relevance Score: 80%

Case of cutaneous malignant melanoma surviving 16 years with late recurrence
Journal of Dermatology, 11/04/09    Relevance Score: 79%

Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma
Cancer, 10/30/09    Relevance Score: 69%

Today in Basic Science/Genetics...keeping you current

Receive free subspecialty "5-minute updates" via email

Is there any relation between serum insulin and insulin-like growth factor-I in non-diabetic patients with skin tag
Journal of the European Academy of Dermatology and Venereology, 12/18/09

Skin pigmentation after NB-UVB and three analogues of prostaglandin F2
Journal of the European Academy of Dermatology and Venereology, 12/16/09

Expression of Ca2+-Activated K+ Channels in Human Dermal Fibroblasts and Their Roles in Apoptosis
Skin Pharmacology and Applied Skin Physiology, 12/16/09

 See all of Basic Science/Genetics

Today in Dermatologic Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

Pathology Review of Thin Melanoma and Melanoma in Situ in a Multidisciplinary Melanoma Clinic: Impact on Treatment Decisions
Journal of Clinical Oncology, 12/18/09

Syringoma of the face treated with fractional photothermolysis
Journal of Cosmetic and Laser Therapy, 12/18/09

Somatostatin receptor scintigraphy in primary cutaneous T- and B-cell lymphomas
Journal of the European Academy of Dermatology and Venereology, 12/18/09

 See all of Dermatologic Oncology